Physician profile
Fatima Shaik
NPI 1801214705
$1,603.91
in general payments reported to CMS, 2019-2025
13 companies · $398 in 2025
The $398 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.72 · 2021: $13.03 · 2022: $154 · 2023: $548 · 2024: $447 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $536.65 | 2022-2024 | Hawkone, Cobalt Dr Mri Surescan, Linq II |
| Actelion Pharmaceuticals US, INC. | $215.85 | 2024-2025 | Opsumit, Opsynvi, Uptravi |
| Novartis Pharmaceuticals Corporation | $186.99 | 2024-2025 | |
| Heartflow, INC. | $124.20 | 2024 | |
| Boston Scientific Corporation | $117.77 | 2020-2024 | Watchman Flx, Watchman |
| E.R. Squibb & Sons, L.L.C. | $82.11 | 2025 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.44 | 2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $79.38 | 2023-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $65.09 | 2023-2024 | Verquvo |
| Biosense Webster, INC. | $49.58 | 2023 | Octaray Mapping Catheter, Carto 3 |
| Pfizer INC. | $24.82 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $21.24 | 2024 | Xarelto |
| Lantheus Medical Imaging, INC. | $20.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Shaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.